Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News CNS Pharmaceuticals Inc. CNSP

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CNSP)

Fundamentals Snapshot (NDAQ:CNSP)

Current News (NDAQ:CNSP)

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

PR Newswire 5 days ago

CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)

PR Newswire 10 days ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire September 7, 2022

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 15, 2022

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

PR Newswire July 25, 2022

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

PR Newswire June 23, 2022

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

PR Newswire June 8, 2022

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

PR Newswire May 24, 2022

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

PR Newswire May 18, 2022

Opinion & Analysis (NDAQ:CNSP)

No current opinion is available.

Bullboard Posts (NDAQ:CNSP)

RE:Nasal will not allow stock price to remain below a dollar

Nasdaq will not allow stock price to remain below a dollar *
Trippleline1 - January 21, 2022

Nasal will not allow stock price to remain below a dollar

Either the company is going to have to come up with some impressive results or we're going to see a stock consolidation. It's...
Trippleline1 - January 21, 2022

Let the dilution begin.

It looks like the stock was purposely driven down to give the buyers of the private placement shares under a dollar. What doesn't...
Trippleline1 - January 6, 2022

Breaking News From Bio Pharma Company CNSP!

BioMedNewsBreaks - April 16th 2021 CNS Pharmaceuticals Inc.'s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than...
Stockjayz - April 18, 2021

If CNSP (Nasdaq) Passes Their FDA Approved Phase 2...

If CNSP Pharmaceuticals Passes Their Phase 2, after some DD last night, and Analysts Reviews, This Could Be a $300-$400 stock! ...
Stockjayz - April 16, 2021

CNSP Pharmaceuticals Rated Strong Buy!

CNS Pharmaceuticals (CNSP) https://finance.yahoo.com/news/2-strong-buy-penny-stocks-165357551.html We will start with CNS...
Stockjayz - April 15, 2021